- Home
- Products
- Customized FluoroAb™
- CD40
- Teneliximab-iFluor 405
Teneliximab-iFluor 405 (CAT#: ADC-FL-740)
This product is comprised of an anti-CD40 monoclonal antibody (Teneliximab) labeled with iFluor 405. iFluor 405 is a blue-fluorescent dye and it's excitation/emission is 401/421 nm.
- TARGET
- ANTIBODY
- DYE
- Name
- CD40
- Alternative Names
- CD40; CD40 molecule, TNF receptor superfamily member 5; TNFRSF5, tumor necrosis factor receptor superfamily, member 5; tumor necrosis factor receptor superfamily member 5; Bp50; p50; CD40L receptor; CD40 type II isoform; B cell-associated molecule; B cell surface antigen CD40; B-cell surface antigen CD40; CD40 antigen (TNF receptor superfamily member 5); tumor necrosis factor receptor superfamily, member 5; nerve growth factor receptor-related B-lymphocyte activation molecule; CDW40; TNFRSF5; MGC9013;
- Overview
- This gene is a member of the TNF-receptor superfamily. The encoded protein is a receptor on antigen-presenting cells of the immune system and is essential for mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. AT-hook transcription factor AKNA is reported to coordinately regulate the expression of this receptor and its ligand, which may be important for homotypic cell interactions. Adaptor protein TNFR2 interacts with this receptor and serves as a mediator of the signal transduction. The interaction of this receptor and its ligand is found to be necessary for amyloid-beta-induced microglial activation, and thus is thought to be an early event in Alzheimer disease pathogenesis. Mutations affecting this gene are the cause of autosomal recessive hyper-IgM immunodeficiency type 3 (HIGM3). Multiple alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.
- Overview
- Chimeric Anti-CD40 IgG1 antibody, Teneliximab
- Generic name
- Teneliximab
- Species Reactivity
- Human
- Name
- iFluor 405
- Color
- Blue
- Excitation⁄Emission (nm)
- 401/421
- Detection method
- Fluorescent
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-FL-740. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
| CAT# | Product Name | Linker | Payload |
| ADC-W-901 | Anti-CD40 (Dacetuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-911 | Anti-CD40 (Lucatumumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-903 | Anti-CD40 (Teneliximab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| ADC-W-913 | Anti-CD40 (Lucatumumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-907 | Anti-CD40 (Teneliximab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-CXCR4 MAb (Clone 1)-iFluor® 440 Succinimidyl Ester (CAT#: WJY0-LS5036)
- Anti-FAT1 MAb (Clone 1)-iFluor® 405 Succinimidyl Ester (CAT#: WJY0-LS1844)
- Anti-CD4 MAb (Clone 14)-iFluor® 350 Succinimidyl Ester (CAT#: WJY0-LS1147)
- Anti-MSLN MAb (Clone 9)-iFluor® 546 Succinimidyl Ester (CAT#: WJY0-LS14848)
- Anti-CD22 MAb (Clone 16)-iFluor® 460 Succinimidyl Ester (CAT#: WJY0-LS8099)
- Anti-CD22 MAb (Clone 17)-iFluor® 532 Succinimidyl Ester (CAT#: WJY0-LS12767)
- Anti-FAP MAb (Clone 3)-iFluor® 555 Succinimidyl Ester (CAT#: WJY0-LS16447)
- Anti-CCL2 MAb (Clone 2)-iFluor® 488 Succinimidyl Ester (CAT#: WJY0-LS10062)
- Anti-FOLH1 MAb (Clone 9)-iFluor® 430 Succinimidyl Ester (CAT#: WJY0-LS3994)
- Anti-SLC3A2 MAb (Clone 2)-iFluor® 532 Succinimidyl Ester (CAT#: WJY0-LS13359)
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.